Business Commons^™

Contracting Mechanisms For Stable Sourcing Networks, Jennifer K. Ryan, Lusheng Shao, Daewon Sun

Department of Supply Chain Management and Analytics: Faculty and Staff Publications

Problem definition: We study profit allocation for a sourcing network, in which a buyer sources froma set of differentiated suppliers with limited capacity under uncertain demand for the final product. Whereas the buyer takes the lead in forming the sourcing network and designing the contract mechanism, due to their substantial bargaining power, the suppliers take the lead in determining the terms of the contract. Academic/practical relevance: We identify contracting mechanisms that will ensure the stability of the sourcing network in the long term, where a stable sourcing network requires an effective profitallocation scheme that motivates all members to …

Inventory Sharing And Demand-Side Underweighting, Hui Zhao, Liang Xu, Enno Siemsen

Department of Supply Chain Management and Analytics: Faculty and Staff Publications

Problem definition: Transshipment/inventory sharing has been used in practice because of its risk-pooling potential. However, human decision makers play a critical role in making inventory decisions in an inventory sharing system, which may affect its benefits. We investigate whether the opportunity to transship inventory influences decision makers’ inventory decisions and whether, as a result, the intended risk-pooling benefits materialize.

Academic/practical relevance: Previous research in transshipment, which is focused on finding optimal stocking and sharing decisions, assumes rational decision making without any systematic bias. As one of the first to study inventory sharing from a behavioral perspective, …

Inducing Compliance With Post-Market Studies For Drugs Under Fda’S Accelerated Approval Pathway, Liang Xu, Hui Zhao, Nicholas C. Petruzzi

Department of Supply Chain Management and Analytics: Faculty and Staff Publications

Problem definition: In 1992, FDA instituted the accelerated approval pathway (AP) to allow promising drugs to enter the market based on limited evidence of efficacy, thereby permitting manufacturers to verify true clinical benefits through post-market studies. However, most postmarket studies have not been completed as promised. We address this non-compliance problem.

Academic/Practical Relevance: The prevalence of this non-compliance problem poses considerable public health risk, thus compromising the original purpose of a well-intentioned AP initiative. We provide an internally consistent and implementable solution to the problem through a comprehensive analysis of the myriad complicating factors and tradeoffs facing FDA.

Methodology: We …